Daniel J. Rader touting Juxtapid under the generic brand name Lomitapide

Here we see the psychopath, down-play the dangers of Lomitapide to promote his professional career as a researcher. The HoFH population is roughly ONE in a million and the cost of this drug is close to $300,000, although the generic version may be slightly cheaper. Aegerion stopped development of Juxtapid/Lomitapide because of the hepatotoxicity issue. An HoFH patient's cholesterol may be lowered, but at what cost--their liver? The population of HoFH suffers is too small and widespread to realize, collectively, the potential danger they face from this drug. Hey--but as long as it will make Daniel J. Rader, M.D. (UPenn) seem a brilliant researcher that develops groundbreaking therapeutic drugs, then Lomitapide has served Dan's selfish purpose.